Mediolanum International Funds Ltd Has $124.61 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Key Points

• Mediolanum International Funds Ltd increased its investment in Eli Lilly and Company by 20.5%, owning 151,497 shares valued at approximately $124.6 million as of the latest reporting period.
• In its most recent quarterly earnings report, Eli Lilly reported $3.34 earnings per share, which fell short of the consensus estimate of $4.64.
• The company has announced a quarterly dividend of $1.50, representing an annual yield of 0.74% with a payout ratio of 48.82%.

Mediolanum International Funds Ltd lifted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 20.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,497 shares of the company's stock after purchasing an additional 25,728 shares during the quarter. Eli Lilly and Company comprises about 1.7% of Mediolanum International Funds Ltd's portfolio, making the stock its 7th biggest position. Mediolanum International Funds Ltd's holdings in Eli Lilly and Company were worth $124,608,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the company. Phoenix Financial Ltd. increased its holdings in Eli Lilly and Company by 30.7% in the first quarter. Phoenix Financial Ltd. now owns 24,889 shares of the company's stock valued at $20,572,000 after buying an additional 5,852 shares during the last quarter. Stevens Capital Management LP purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at $9,941,000. Prescott Group Capital Management L.L.C. raised its holdings in shares of Eli Lilly and Company by 19.3% during the first quarter. Prescott Group Capital Management L.L.C. now owns 1,909 shares of the company's stock worth $1,577,000 after acquiring an additional 309 shares in the last quarter. AM Investment Strategies LLC raised its holdings in Eli Lilly and Company by 7.6% during the first quarter. AM Investment Strategies LLC now owns 1,422 shares of the company's stock valued at $1,175,000 after buying an additional 101 shares in the last quarter. Finally, Longbow Finance SA raised its holdings in Eli Lilly and Company by 68.0% during the first quarter. Longbow Finance SA now owns 30,674 shares of the company's stock valued at $25,334,000 after buying an additional 12,421 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $39.70 during mid-day trading on Tuesday, reaching $768.41. The company's stock had a trading volume of 3,732,558 shares, compared to its average volume of 3,758,750. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The stock has a fifty day moving average of $773.01 and a two-hundred day moving average of $800.67. The firm has a market capitalization of $728.26 billion, a PE ratio of 62.50, a P/E/G ratio of 1.18 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm's revenue was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.58 earnings per share. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Saturday. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price on the stock. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, UBS Group dropped their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus price target of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.